PMID- 40976786
OWN - NLM
STAT- Publisher
LR  - 20250921
IS  - 1460-2075 (Electronic)
IS  - 0261-4189 (Linking)
DP  - 2025 Sep 21
TI  - Telomeric DNA damage response mediates neurotoxicity of Aβ42 oligomers in 
      Alzheimer's disease.
LID - 10.1038/s44318-025-00521-1 [doi]
AB  - Ageing is the major risk factor for Alzheimer's disease (AD), the most common 
      neurodegenerative disorder. DNA damage is a hallmark of ageing, particularly when 
      occurring at telomeres, genomic regions vulnerable to oxidative damage and often 
      challenging for the cell to repair. Here, we show that brains of 3xTg-AD mice, an 
      established AD model characterized by amyloid-β (Aβ)-induced pathology, exhibit 
      increased activation of DNA damage response (DDR) pathways at telomeres. Exposure 
      of mouse primary hippocampal neurons to 42-residue Aβ (Aβ42) oligomers, a 
      significant pathogenetic contributor to AD, triggers telomeric DDR by increasing 
      the levels of reactive oxygen species caused by calcium imbalance. Antisense 
      oligonucleotides targeting non-coding RNAs generated at damaged telomeres in vivo 
      (in 3xTg-AD mice) and in vitro reduce neurotoxicity in iPSC-derived human 
      cortical neurons and mouse primary neurons while inhibiting Aβ42-induced 
      telomeric DDR, and restore transcriptional pathways altered by Aβ and found 
      dysregulated in AD patients. These results unveil an unexpected role of telomeric 
      DNA damage responses in Alzheimer's disease pathogenesis, and suggest a novel 
      target for the development of RNA-based therapies.
CI  - © 2025. The Author(s).
FAU - Sepe, Sara
AU  - Sepe S
AUID- ORCID: 0000-0002-9884-9189
AD  - IFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy.
FAU - Rey, Federica
AU  - Rey F
AUID- ORCID: 0000-0001-7944-3143
AD  - IFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy.
FAU - Mancheno-Ferris, Alexandra
AU  - Mancheno-Ferris A
AUID- ORCID: 0000-0002-2689-8483
AD  - IFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy.
FAU - Bigi, Alessandra
AU  - Bigi A
AUID- ORCID: 0000-0002-1067-6288
AD  - Department of Experimental and Clinical Biomedical Sciences, Section of 
      Biochemistry, University of Florence, Florence, Italy.
FAU - Fani, Giulia
AU  - Fani G
AD  - Department of Experimental and Clinical Biomedical Sciences, Section of 
      Biochemistry, University of Florence, Florence, Italy.
FAU - Damiani, Devid
AU  - Damiani D
AD  - Center for Human Technologies, Non-coding RNAs and RNA-based Therapeutics, 
      Istituto Italiano di Tecnologia (IIT), Genova, Italy.
FAU - Cabrini, Matteo
AU  - Cabrini M
AD  - IFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy.
AD  - Institute of Molecular Genetics (IGM), National Research Institute (CNR), Pavia, 
      Italy.
FAU - Marinelli, Eugenia
AU  - Marinelli E
AD  - IFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy.
FAU - Aguado, Julio
AU  - Aguado J
AD  - IFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy.
AD  - University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
FAU - Contu, Liliana
AU  - Contu L
AD  - Center for Human Technologies, Non-coding RNAs and RNA-based Therapeutics, 
      Istituto Italiano di Tecnologia (IIT), Genova, Italy.
FAU - di Lillo, Alessia
AU  - di Lillo A
AD  - IFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy.
FAU - Boggio, Sara
AU  - Boggio S
AD  - IFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy.
FAU - Tavella, Sara
AU  - Tavella S
AD  - IFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy.
AD  - Institute of Molecular Genetics (IGM), National Research Institute (CNR), Pavia, 
      Italy.
FAU - Rosso, Ilaria
AU  - Rosso I
AD  - IFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy.
FAU - Gustincich, Stefano
AU  - Gustincich S
AD  - Center for Human Technologies, Non-coding RNAs and RNA-based Therapeutics, 
      Istituto Italiano di Tecnologia (IIT), Genova, Italy.
FAU - Chiti, Fabrizio
AU  - Chiti F
AUID- ORCID: 0000-0002-1330-1289
AD  - Department of Experimental and Clinical Biomedical Sciences, Section of 
      Biochemistry, University of Florence, Florence, Italy.
FAU - d'Adda di Fagagna, Fabrizio
AU  - d'Adda di Fagagna F
AUID- ORCID: 0000-0002-9603-5966
AD  - IFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy. 
      fabrizio.dadda@igm.cnr.it.
AD  - Institute of Molecular Genetics (IGM), National Research Institute (CNR), Pavia, 
      Italy. fabrizio.dadda@igm.cnr.it.
LA  - eng
GR  - ERC advanced grant -TELORNAGING-835103/EC | European Research Council (ERC)/
GR  - ERC POC TELOVACCINE - 101113229/EC | European Research Council (ERC)/
GR  - GMR23T2007/Fondazione Telethon (FT)/
GR  - GMR23T2007/Fondazione Telethon (FT)/
GR  - (PRIN) 2020CXFL4T/Ministero dell'Università e della Ricerca (MUR)/
GR  - (PRIN) 2022R7LH5T/Ministero dell'Università e della Ricerca (MUR)/
GR  - FG_24/2020/Fondazione Italiana di Ricerca per la Sclerosi Laterale Amiotrofica 
      (AriSLA)/
GR  - FG_24_2020/Fondazione Italiana di Ricerca per la Sclerosi Laterale Amiotrofica 
      (AriSLA)/
GR  - AIRC-IG 30471/Fondazione AIRC per la ricerca sul cancro ETS (AIRC)/
GR  - AIRC-IG 21762/Fondazione AIRC per la ricerca sul cancro ETS (AIRC)/
GR  - AIRC 5×1000 21091/Fondazione AIRC per la ricerca sul cancro ETS (AIRC)/
GR  - Next generation EU,PE8 Project Age-It/European Commission (EC)/
GR  - Next generation EU,PE8 Project Age-It/European Commission (EC)/
GR  - Investment CN3 National Center for Gene Therapy and Drugs based on RNA 
      Technology/European Commission (EC)/
GR  - NEXTGENERATIONEU/European Commission (EC)/
GR  - DSB.AD004.294/POR FESR InterSLA/
GR  - EJPRD19-206 PROGERIA,GA 825575/Fondazione Regionale per la Ricerca Biomedica 
      (Regione Lombardia)/
PT  - Journal Article
DEP - 20250921
PL  - England
TA  - EMBO J
JT  - The EMBO journal
JID - 8208664
SB  - IM
OTO - NOTNLM
OT  - ASO
OT  - Aging
OT  - Alzheimer’s disease (AD)
OT  - DNA damage response (DDR)
OT  - Telomeres
COIS- Disclosure and competing interest statement. F.d’A.d.F. is an inventor on the 
      patent applications RNA products and uses thereof (PCT/EP2013/ 059753) and 
      therapeutic oligonucleotides (PCT/EP2016/068162). F.d’A.d.F. is a shareholder of 
      TAG Therapeutics. The remaining authors declare no competing interests.
EDAT- 2025/09/22 00:30
MHDA- 2025/09/22 00:30
CRDT- 2025/09/21 23:12
PHST- 2024/11/18 00:00 [received]
PHST- 2025/07/04 00:00 [accepted]
PHST- 2025/07/01 00:00 [revised]
PHST- 2025/09/22 00:30 [medline]
PHST- 2025/09/22 00:30 [pubmed]
PHST- 2025/09/21 23:12 [entrez]
AID - 10.1038/s44318-025-00521-1 [pii]
AID - 10.1038/s44318-025-00521-1 [doi]
PST - aheadofprint
SO  - EMBO J. 2025 Sep 21. doi: 10.1038/s44318-025-00521-1.
